Country websites

Building the Momentum

Facts & Figures 2024

Who we are

Creating a future worth living. For patients. Worldwide. Every day.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which approximately 4.2 million patients worldwide regularly undergo dialysis treatment. United by a shared purpose of creating a future worth living for chronically and critically ill people, we care for around 299,000 dialysis patients around the globe. Their well-being always comes first.

It is our mission to provide the best possible care for a growing number of patients sustainably in diverse health care systems. As a vertically integrated company, our portfolio encompasses a comprehensive range of high-quality health care products and services as well as various dialysis treatment options for both in-center and home dialysis.

employees worldwide

Around

112,000

employees worldwide

dialysis centers in around 50 countries

Around

3,700

dialysis centers in around 40 countries

Products in around

Products in around

150

countries

dialysis treatments in 2023

Around

48 M

dialysis treatments in 2024

patients worldwide

Around

299,000

patients worldwide

of our patients would highly recommend our services

78 %

of our patients would highly recommend

our services

production sites in around 20 countries

Around

40

production sites in around 20 countries

dialyzers sold in 2023

Around

174 M

dialyzers sold in 2024

share in hemodialysis machines market

Around

50 %

share in hemodialysis machines market

Building the Momentum

We successfully completed a challenging year, consistently continued our transformation and always placed the well-being of our patients at the center of our actions. 

Helen Giza Chief Executive Officer

The year 2024 was about building momentum: operationalizing and further optimizing our operating model with a mission to deliver the highest quality of patient care, enhancing financial returns, and creating value for our shareholders. I am proud to say that we have more than delivered on our commitments and are ideally positioned for the future.

Helen Giza

Chief Executive Officer and Chair of the Management Board

Revenue

Revenue Solid organic growth

Operating income

Operating income

Net income

Growth driven by favorable business development

Dividend per share

Dividend per share